Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback